Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dermira Inc (DERM)

Dermira Inc (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,022,269
  • Shares Outstanding, K 54,521
  • Annual Sales, $ 42,340 K
  • Annual Income, $ -221,540 K
  • 60-Month Beta 1.56
  • Price/Sales 11.00
  • Price/Cash Flow N/A
  • Price/Book 70.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.58
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/25/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.39
  • Number of Estimates 2
  • High Estimate -1.14
  • Low Estimate -1.64
  • Prior Year -1.70
  • Growth Rate Est. (year over year) +18.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.68 +0.37%
on 01/27/20
19.24 -2.55%
on 01/21/20
-0.41 (-2.11%)
since 01/17/20
3-Month
7.66 +144.78%
on 12/06/19
19.48 -3.75%
on 01/10/20
+10.70 (+132.92%)
since 11/19/19
52-Week
5.25 +257.14%
on 10/16/19
19.48 -3.75%
on 01/10/20
+11.16 (+147.04%)
since 02/19/19

Most Recent Stories

More News
Lilly Completes Acquisition of Dermira

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of...

LLY : 154.17 (+1.11%)
DERM : 18.75 (+0.05%)
(DERM) Alert: Johnson Fistel Continues Investigation of Proposed Sale of Dermira, Inc. for $19.30

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) ("Dermira") breached their fiduciary duties in connection with...

LLY : 154.17 (+1.11%)
DERM : 18.75 (+0.05%)
CSFL, DLPH, DERM, and HXL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

Rigrodsky & Long, P.A. announces that it is investigating:

CSFL : 18.14 (+4.67%)
DERM : 18.75 (+0.05%)
SSB : 51.35 (-2.58%)
DLPH : 16.74 (-1.06%)
HXL : 37.49 (-4.99%)
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

LLY : 154.17 (+1.11%)
AMGN : 247.72 (-0.15%)
DERM : 18.75 (+0.05%)
TEVA : 9.48 (+2.05%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds CBB, HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations

EQNX::TICKER_START (NYSE:CBB),(NasdaqGM:HABT),(NASDAQ:DERM),(NasdaqGM:MFSF), EQNX::TICKER_END

CBB : 15.08 (+0.27%)
HABT : 13.98 (+0.94%)
DERM : 18.75 (+0.05%)
MFSF : 24.87 (-0.20%)
Lifshitz & Miller LLP Announces Investigation of AquaVenture Holdings Limited, CenterState Bank Corporation, Dermira, Inc., The Habit Restaurants, Inc., Hexcel Corporation, LogMeIn, Inc., Telaria, Inc, and TiVo Corporation

AquaVenture Holdings Limited (WAAS)

WAAS : 27.03 (-0.11%)
CSFL : 18.14 (+4.67%)
DERM : 18.75 (+0.05%)
HABT : 13.98 (+0.94%)
HXL : 37.49 (-4.99%)
LOGM : 86.04 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - HABT, DERM, HXL, PRMW

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

HABT : 13.98 (+0.94%)
DERM : 18.75 (+0.05%)
HXL : 37.49 (-4.99%)
PRMW : 14.60 (unch)
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.

MRK : 85.81 (+0.20%)
NVS : 90.94 (-0.03%)
LLY : 154.17 (+1.11%)
DERM : 18.75 (+0.05%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds HABT, DERM, and MFSF Shareholders About Its Ongoing Investigations

EQNX::TICKER_START (NASDAQ:HABT),(NASDAQ:DERM),(NasdaqGM:MFSF),(NASDAQ:NWBI), EQNX::TICKER_END

HABT : 13.98 (+0.94%)
DERM : 18.75 (+0.05%)
MFSF : 24.87 (-0.20%)
NWBI : 9.95 (-1.68%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - CBB, HABT, DERM, IBKC

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CBB : 15.08 (+0.27%)
HABT : 13.98 (+0.94%)
DERM : 18.75 (+0.05%)
IBKC : 43.08 (-5.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade DERM with:

Business Summary

Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage...

See More

Key Turning Points

2nd Resistance Point 18.78
1st Resistance Point 18.77
Last Price 18.75
1st Support Level 18.74
2nd Support Level 18.72

See More

52-Week High 19.48
Last Price 18.75
Fibonacci 61.8% 14.04
Fibonacci 50% 12.36
Fibonacci 38.2% 10.69
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar